SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Alphabet, Inc. is a holding company, which engages in software, health care, transportation, and other technologies. It operates through the following segments: Google Services, Google Cloud, and Other Bets. The Google Services segment includes products and services, such as ads, Android, Chrome, devices, Google Maps, Google Play, Search, and YouTube. The Google Cloud segment refers to infrastructure and platform services, collaboration tools, and other services for enterprise customers. The Other Bets segment relates to the sale of healthcare-related services and internet services. The company was founded by Lawrence E. Page and Sergey Mikhaylovich Brin on October 2, 2015 and is headquartered in Mountain View, CA.

Alphabet Inc - Ordinary Shares - Class A

Alphabet Inc Class A

Alphabet is trending with high anticipation ahead of its earnings report, as the community eagerly discusses whether its AI advancements like Gemini and strong cloud growth can deliver a market-saving beat amidst broader tech sector uncertainty, or if a 'sell the news' reaction is likely after its recent significant run.

Snap, Inc. operates as a technology company, which engages in the provision of a visual messaging application that was created to help people communicate through short videos and images. The company was founded by Frank Reginald Brown IV, Evan Thomas Spiegel, and Robert C. Murphy in 2010 and is headquartered in Santa Monica, CA.

Snap Inc - Ordinary Shares - Class A

Snap Inc

Snap Inc. is heavily discussed ahead of its earnings report, with community sentiment divided between optimists highlighting its vast user base and potential for monetization amidst oversold conditions, and skeptics focusing on its consistent profitability challenges, intense competition, and management issues compounded by growing concerns over social media restrictions for minors.

Alphabet Inc - Ordinary Shares - Class C

Alphabet is trending ahead of its upcoming earnings report, as the community debates whether its strong AI momentum with Gemini and Waymo will drive a market rally or if a "sell the news" reaction will trigger a broader tech sector pullback following its significant run.

Advanced Micro Devices, Inc. engages in the provision of semiconductor businesses. It operates through the following segments: Data Center, Client, Gaming, and Embedded. The Data Center segment includes server-class CPUs, GPUs, AI accelerators, DPUs, FPGAs, SmartNICs, and Adaptive SoC products. The Client segment refers to the computing platforms, which are a collection of technologies that are designed to work together to provide a more complete computing solution. The Gaming segment is a fundamental component across many products and can be found in APU, GPU, SoC or a combination of a discrete GPU with another product working in tandem. The Embedded segment focuses on the embedded CPUs, GPUs, APUs, FPGAs, and Adaptive SoC products. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

Advanced Micro Devices is trending after its strong Q4 earnings were overshadowed by conservative Q1 guidance, particularly concerning AI chip sales to China, triggering a significant sell-off across the semiconductor sector. The community is divided between those buying the dip, seeing an overreaction given long-term AI demand, and others who view the guidance as a necessary reality check on high valuations.

QUALCOMM, Inc. engages in developing and commercializing foundational technologies and products used in mobile devices and other wireless products. It operates through the following segments: Qualcomm CDMA Technologies (QCT), Qualcomm Technology Licensing (QTL), and Qualcomm Strategic Initiatives (QSI). The QCT segment develops and supplies integrated circuits and system software based on technologies for use in voice and data communications, networking, application processing, multimedia, and global positioning system products. The QTL segment grants licenses and provides rights to use portions of the firm's intellectual property portfolio. The QSI segment focuses on opening new or expanding opportunities for its technologies and supporting the design and introduction of new products and services for voice and data communications. The company was founded by Franklin P. Antonio, Adelia A. Coffman, Andrew Cohen, Klein Gilhousen, Irwin Mark Jacobs, Andrew J. Viterbi, and Harvey P. White in July 1985 and is headquartered in San Diego, CA.

Qualcomm, Inc.

Qualcomm is actively discussed after its strong financial report, with the community balancing optimism for its AI and automotive growth against concerns regarding guidance and persistent competitive pressures in the semiconductor market.

Arm Holdings Plc engages in the licensing, marketing, research, and development of microprocessors, systems IP, graphics processing units, physical IP and associated systems IP, software, and tools. It operates through the following geographical segments: United Kingdom, United States, and Other Countries. The company was founded on November 12, 1990 and is headquartered in Cambridge, the United Kingdom.

Arm Holdings plc. - ADR

Arm Holdings Plc.

Arm Holdings is the subject of intense investor conversation, grappling with concerns over its premium valuation and market reactions to guidance, even as its foundational technology is critical for advancing AI, robotics, and data center compute. The community is deeply split, with many highlighting its expanding "Physical AI" division and strategic position, while others remain skeptical about its near-term execution and market performance.

e.l.f. Beauty, Inc. is a holding company, which engages in the provision of inclusive, accessible, clean, vegan and cruelty free cosmetics and skin care products. The company focuses on the e-commerce, national retailers and international business channels. Its brands include elf, elf skin, naturium, well people, and keys soulcare. The company was founded in 2004 and is headquartered in Oakland, CA.

e.l.f. Beauty Inc

e.l.f. Beauty is trending following mixed earnings, where an EPS beat was overshadowed by slightly missed revenue and lowered guidance, causing a sharp decline in share price. The community is actively debating whether this presents an oversold buying opportunity or reflects ongoing concerns about growth and tariff impacts.

Broadcom Inc. is a global technology company, which designs, develops, and supplies semiconductors and infrastructure software solutions. It operates through the Semiconductor Solutions and Infrastructure Software segments. The Semiconductor Solutions segment refers to product lines and intellectual property licensing. The Infrastructure Software segment relates to mainframe, distributed and cyber security solutions, and fibre channel storage area networking business. The company was founded in 1961 and is headquartered in Palo Alto, CA.

Broadcom Inc

Broadcom is surging amid heightened community discussion driven by Google's substantial capital expenditure, signaling strong demand for its AI infrastructure, and fresh speculation about a massive custom silicon deal with OpenAI, positioning it as a key beneficiary in the rapidly expanding AI sector.

TeraWulf, Inc. owns and operates fully integrated environmentally clean bitcoin mining facilities in the United States. TeraWulf will generate domestically produced bitcoin powered by nuclear, hydro and solar energy. The company was founded by Paul Prager and Nazar Khan on February 8, 2021 and is headquartered in Easton, MD.

TeraWulf Inc

TeraWulf is trending after announcing the acquisition of two new strategic sites that more than double its digital and power capacity to 2.8 GW, significantly advancing its pivot into AI and high-performance computing. This transformative news is fueling community discussion about a potential short squeeze and a major re-valuation of the stock, with many expecting further decoupling from Bitcoin's performance.

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Lilly(Eli) & Co

Eli Lilly is surging due to strong earnings and an elevated 2026 outlook, fueled by robust demand for its Mounjaro and Zepbound drugs, solidifying its competitive leadership in the rapidly expanding GLP-1 market. The community is actively discussing its sustained growth trajectory and strategic initiatives, including a major AI partnership.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Corvus Pharmaceuticals Stock Rallies 209% in a Month: Here's Why

CRVS stock surges 209% in a month after positive cohort 4 phase I data show durable eczema responses for soquelitinib.

Corvus Pharmaceuticals (CRVS) Is Up 211.80% in One Week: What You Should Know 

Does Corvus Pharmaceuticals (CRVS) have what it takes to be a top stock pick for momentum investors? Let's find out.

Wall Street Analysts Think Corvus (CRVS) Could Surge 25.29%: Read This Before Placing a Bet

The average of price targets set by Wall Street analysts indicates a potential upside of 25.3% in Corvus (CRVS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Corvus Pharmaceuticals (NASDAQ:CRVS) Shares Down 9.3% - Here's What Happened

Corvus Pharmaceuticals (NASDAQ:CRVS) Stock Price Down 9.3% - Here's What Happened...

Corvus Pharmaceuticals Shares New Phase I Soquelitinib Data Showing Strong AD EASI Gains

Corvus Pharmaceuticals (NASDAQ:CRVS) presented new Phase I results for oral soquelitinib in moderate-to-severe atopic dermatitis (AD), highlighting updated efficacy, durability, and safety findings...

Corvus Pharmaceuticals (NASDAQ:CRVS) Shares Gap Up - Here's What Happened

Corvus Pharmaceuticals (NASDAQ:CRVS) Shares Gap Up - Here's Why...

<ul class="summary-bullets"><li>Corvus stated that it intends to use the net proceeds from this stock offering to meet its working capital and general corporate purpose needs.</li><li>This may include capital expenditures, as well as research and development costs for its Phase 3 T cell lymphoma, and Phase 2 atopic dermatitis, hidradenitis suppurativa, and asthma clinical trials.</li><li>The company expects to close the offering on or about Jan. 23, 2026.</li></ul>Corvus Pharmaceuticals Inc. (CRVS) shares were up&nbsp;more than 7% in&nbsp;Thursday’s&nbsp;pre-market trade after the company announced an upsized public stock offering.Corvus increased its public stock offering to $175 million from $150 million, making 7.9 million shares of its common stock available for purchase at Wednesday’s closing price of $22.15. The company stated that underwriters have a 30-day option to purchase an additional 1.18 million shares.The company expects to close the offering on or about Jan. 23, 2026.<h2 class="st-heading-2">Use Of Net Proceeds</h2>Corvus stated that it intends to use the net proceeds from this stock offering to meet its working capital and general corporate purpose needs.This may include capital expenditures, as well as research and development costs for its Phase 3 T cell lymphoma, and Phase 2 atopic dermatitis, hidradenitis suppurativa and asthma clinical trials, sales and marketing and administrative expenses.<h2 class="st-heading-2">Positive Atopic Dermatitis Trial Results</h2>Corvus&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/why-is-crvs-stock-rising-today/cmUuNzGR4aM">announced</a> on Tuesday that cohort 4 of its placebo-controlled trial showed favorable safety and efficacy results, consistent with those of the previous three cohorts.Corvus stated that all patients in cohort 4 had completed the 56-day treatment course and had similar baseline characteristics to those in the previous cohort. However, they had a higher mean baseline EASI (Eczema Area and Severity Index) score compared to patients in cohorts 1 and 2.“The results from cohort 4 increase our confidence that soquelitinib could become a leading oral therapy for the treatment of atopic dermatitis,” said Corvus CEO Richard A. Miller.<h2 class="st-heading-2">Retail Sounds Optimistic</h2>Retail sentiment on Stocktwits around&nbsp;<a href="https://stocktwits.com/symbol/CRVS">Corvus Pharmaceuticals</a> was in the ‘bullish’ territory at the time of writing, while message volume was at ‘extremely high’ levels.One bullish user on the platform pointed to inbound partnerships and institutional buying, stating that the stock could “double again soon.”<stembedurl>https://stocktwits.com/fubar444/message/642514507</stembedurl>Another user stated that the CRVS stock will “rocket” once the offering closes.<stembedurl>https://stocktwits.com/SleepyDon/message/642502522</stembedurl><a href="https://stocktwits.com/symbol/CRVS">CRVS stock</a> is up 188% year-to-date and 324% over the past 12 months.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/apple-indian-antitrust-regulator-prevent-global-financial-records-38-billion-fine/cmUzwavR4QZ">Apple Seeks To Prevent India’s Antitrust Regulator From Accessing Global Financial Records As It Fears A $38 Billion Fine: Report</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Corvus Pharmaceuticals logo is seen displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

CRVS Stock Surges Pre-Market After Corvus Expands Equity Raise To $175 Million

Corvus increased its public stock offering to $175 million from $150 million, making 7.9 million shares of its common stock available for purchase at Wednesday’s closing price of $22.15.

Equity

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Given Average Rating of "Moderate Buy" by Brokerages

Shares of Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS - Get Free Report) have been given an average recommendation of "Moderate Buy" by the six research firms that are presently covering the firm...

<ul class="summary-bullets"><li>Futures edged higher as markets processed renewed tariff tensions and bond market moves.</li><li>U.S. stocks posted their steepest one-day drop since October.</li><li>After-hours trading was driven by Netflix’s spending and deal plans, Corvus’s stock offering, GameStop’s insider buying and United Airlines’ updated outlook.</li></ul>U.S. stock futures traded modestly higher on Tuesday night after Wall Street logged its worst session in three months, as renewed trade tensions and moves in bond markets kept investors on edge.&nbsp;As of 10.23 p.m. ET, Nasdaq 100 futures and&nbsp; S&amp;P 500 futures were up 0.3%, while Dow futures rose 0.2%.On Stocktwits, retail sentiment toward the SPDR S&amp;P 500 ETF Trust (SPY) and the Invesco QQQ Trust (QQQ) was ‘extremely bearish’ amid ‘high’ message volume, while sentiment toward the SPDR Dow Jones Industrial Average ETF Trust (DIA) was ‘bearish’ amid ‘extremely high’ message volume.<h2 class="st-heading-2">Market Drivers</h2>Markets reacted after U.S. equities posted their steepest declines since October, with investors moving to reduce risk amid trade tensions and stress in global bond markets.In the prior session, the Dow Jones Industrial Average fell more than 870 points, or about 1.8%, while the S&amp;P 500 slid roughly 2.1% and the Nasdaq Composite dropped 2.4%. All three benchmarks logged their worst daily performances since Oct. 10, with the S&amp;P 500 and Nasdaq slipping into negative territory for 2026.The selloff came after U.S. President Donald Trump renewed his push to take control of Greenland, alongside threats to impose tariffs on several European nations. Trump said tariffs on European imports would begin in February and rise further later in the year if no agreement is reached. The comments came ahead of Trump’s scheduled appearance at the World Economic Forum in Davos on Wednesday.<h2 class="st-heading-2">Trending Stocks To Watch</h2>Netflix (NFLX): Shares slid about 5% in after-hours trading after the company said it&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/netflix-flags-heavier-2026-content-spend-pressuring-margins-as-wbd-deal-overhang-drags-stock/cmUDaiVR4ON">plans to step up content spending this year</a> and move forward with an all-cash bid for Warner Bros. Discovery’s studio and streaming assets.Apple (AAPL): Shares rose slightly in extended trading&nbsp;as investors nervously eyed&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/aapl-shares-dip-ahead-of-q1-results-retail-says-buy-the-dip/cmUuDlzR4Og">next week’s earnings</a>; Citi lowered its price target, while Evercore ISI added the stock to its ‘Tactical Outperform’ list.Corvus Pharmaceuticals (CRVS): Shares fell 5% in extended trading after the company&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/corvus-pharma-stock-dips-after-hours-following-best-day-ever/cmUDaWJR4OZ">announced a $150 million stock offering</a>, following a record rally fueled by positive eczema trial data and a wave of analyst price target hikes.GameStop (GME): Shares climbed more than 3% after hours as&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/gme-stock-edges-up-after-hours-as-ceo-increases-stake-in-retailer/cmUu6n5R4Oj">chairman and CEO Ryan Cohen disclosed additional share purchases</a>, lifting his stake in the company to roughly 9.2%.United Airlines (UAL): Shares jumped more than 3% in extended trading after the company issued an&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/ual-shares-rise-after-hours-on-upbeat-guidance-q4-earnings-beat/cmUuyjCR4Oi">upbeat outlook for 2026</a> on the back of a stronger-than-expected fourth quarter.<h2 class="st-heading-2">Broader Markets</h2>In broader markets, gold climbed to fresh record levels, trading near $4,800 an ounce as investors sought safety amid geopolitical tensions. The 10-year U.S. Treasury yield remained elevated, briefly climbing 4.3% following the prior session’s surge. Meanwhile, Silver traded near $95 an ounce, hovering just below its recent record high.Asian stocks fell for a third straight session on Wednesday. MSCI’s broad index of Asia-Pacific stocks outside Japan was down in early trade, with Japan’s Nikkei dropping for a fifth straight session.West Texas Intermediate crude oil prices for March fell 1.31% to $59.57 a barrel.Among the catalysts for the day are corporate earnings from companies including Johnson &amp; Johnson, Halliburton, and Travelers, along with fresh U.S. housing data covering construction activity and pending home sales.For updates and corrections, email newsroom[at]stocktwits[dot]com.

The Wall Street bull stands in the financial district near the New York Stock Exchange (NYSE) on November 18, 2025 in New York City. (Photo by Spencer Platt/Getty Images)

Dow, Nasdaq, S&P 500 Futures Tick Higher After Wall Street’s Worst Day In 3 Months: Why NFLX, AAPL, CRVS, GME, UAL Are In Focus Today

Markets looked to stabilize overnight as investors weighed geopolitical developments amid a busy earnings schedule.

<ul class="summary-bullets"><li>The company announced a $150 million public stock offering, including common shares and pre-funded warrants.</li><li>Proceeds are expected to support ongoing clinical programs, including late-stage lymphoma research and multiple mid-stage skin and respiratory trials.</li><li>Several Wall Street firms raised their price targets following the release of positive Soquelitinib data.</li></ul>Corvus Pharmaceuticals Inc. shares slid in&nbsp;extended trading on Tuesday after the company announced a $150 million public stock offering,&nbsp;following their best session on record&nbsp;that was driven by positive results from an atopic dermatitis trial and multiple analyst price target upgrades.The stock surged 166% to close&nbsp;at a record high of $21.41 on Tuesday, before&nbsp;dipping&nbsp;over 6% in after-hours trading.&nbsp;<h2 class="st-heading-2">Stock Offering Weighs On Shares</h2>Corvus said it has launched an underwritten public offering of $150 million, consisting of common shares and pre-funded warrants offered to certain investors. The company said underwriters will also have a 30-day option to purchase up to an additional $22.5 million in shares at the offering price, before fees and commissions.Corvus said the funds will be used to support general corporate operations, including capital expenses and continued research and development. That covers research into its Phase 3 program for T cell lymphoma, as well as Phase 2 studies for atopic dermatitis, hidradenitis suppurativa, and asthma, and also sales, marketing, and administrative expenses.<h2 class="st-heading-2">Rally Driven By Positive Eczema Data</h2>Earlier in the day,&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/why-is-crvs-stock-rising-today/cmUuNzGR4aM">Corvus reported positive results</a> from cohort 4 of its placebo-controlled study of Soquelitinib in atopic dermatitis.Corvus&nbsp;reported that all patients enrolled in the cohort completed 56 days of treatment and had baseline characteristics generally consistent with those of previous cohorts. However, their mean Eczema Area and Severity Index score was&nbsp;higher than that of&nbsp;cohorts 1 and 2.The company said 75% of patients saw their eczema improve by at least 75%, while 25% experienced a 90% or greater improvement after treatment with Soquelitinib. Corvus also&nbsp;reported that about a third of patients had an Investigator Global Assessment score of 0 or 1, indicating the disease was rated as clear or almost clear.“The results from cohort 4 increase our confidence that Soquelitinib could become a leading oral therapy for the treatment of atopic dermatitis,” CEO Richard Miller said in a statement.<h2 class="st-heading-2">Analysts Raise Price Targets</h2>Following the data release, H.C. Wainwright raised the firm’s price target to $27 from $11 and maintained a 'Buy' rating, citing “game-changing” topline results from cohort 4 of the Phase 1 study of Soquelitinib in refractory atopic dermatitis. Based on the findings, the firm said it increased its projected market penetration assumption to 30% from 10%.Barclays also raised its price target to $28 from $16 and maintained an 'Overweight' rating after the company reported positive Phase 1 data.Mizuho raised its price target to $20 from $13 and reiterated an 'Outperform' rating. The firm said the new data were “outstanding” and support its view of Soquelitinib as a potential best-in-disease agent in atopic dermatitis. Mizuho added that Corvus remains a top pick for January.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment for Corvus ended on an ‘extremely bullish’ (97/100) note, with the score hitting a lifetime high; 24-hour message volume spiked by more than 10,000%, and watchers jumped by nearly 9%.<figure class="image"><img src="https://news.stocktwits-cdn.com/crvs_ss_png_4273cfb302.webp" alt="crvs ss.png" width="970" height="143"><figcaption>CRVS sentiment and message volume as of January 20 | Source: Stocktwits</figcaption></figure>One user said, “Truth be told, I would have preferred a partnership announcement today, not a public offering. But they did what they had to do. You don't leave money on the table.”<stembedurl>https://stocktwits.com/ObserverOne/message/642364378</stembedurl>Another bearish user said, “Sick market, phase 1 hype, expected dilution, and it largely sticks the landing. Makes no sense.”<stembedurl>https://stocktwits.com/Tradebub/message/642369471</stembedurl><a href="https://stocktwits.com/symbol/CRVS">Corvus’ stock</a> has&nbsp;soared 327% over the past 12 months.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Corvus Pharma Stock Dips Over 6% After-Hours Following Best Day Ever — What Went Wrong?

The update follows the company’s release of cohort 4 data from its atopic dermatitis study of Soquelitinib.

Corvus Pharmaceuticals, Inc. engages in the development of immune modulator product candidates with the potential to treat solid cancers, T-cell lymphomas, autoimmune diseases, and infectious diseases. Its product pipeline includes B Cell Activator and Anti-CD73, Adenosine Production Inhibitor Anti-CD73, ITK Inhibitor, A2AR Inhibitor, Anti-CXCR2, and A2BR Inhibitor. The company was founded by Richard A. Miller, Peter A. Thompson, Joseph J. Buggy, and Erik Verner on January 27, 2014 and is headquartered in South San Francisco, CA.

Corvus Pharmaceuticals Inc

Beat EPS and revenue

Beat EPS, miss revenue

Miss EPS, beat revenue

Miss EPS and revenue

What do you expect from $AMZN earnings on Thursday?

Current Price	$20.82
Prev Close	$21.34
Open	$21.44
Dividend Yield	0.00%
50-Day Moving Average	$11.02
Beta	1.36
Avg. Volume	7.73M
PE Ratio	-39.90

52-Week High	$26.95
52-Week Low	$2.54
Market Capitalization	$1.79B
EPS (Annual)	-$1.02
Price to Book	22.21
Revenue Per Employee	$0.00
Enterprise Value/EBITDA	N/A

CRVS
Corvus Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest CRVS News

CRVSCorvus Pharmaceuticals Inc